|Day Low/High||323.95 / 327.43|
|52 Wk Low/High||201.44 / 333.96|
The maker of medical and industrial products had been underperforming the broader market but looks primed to move higher.
Canada made the developed world's first moves toward normalizing monetary policy coming out of the pandemic, despite the fact that Canada does not seem to be flattening its own curve.
There's a whole lotta lovin' going around this name.
Here's the kind I like to buy -- and the vetted stocks that you can play on 'good' risk.
I do not find enough technical reasons to recommend new long positions at this point in time.
Several sessions over the past 10 days have seen increased trading volume at the NYSE, but not the Nasdaq, and for the S&P 500, but not the Nasdaq Composite. Is this professional risk reduction?
The charts of the life sciences company suggest its stock could make a large upside move.
Earnings reports continue to outperform, but can this support equity markets at these levels now?
This list is not a buy list but a list of stocks that have been brought to new heights.
As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.
Despite the dramatic and highly negative decline in economic activity that forced algos to hit the markets from above, enough portfolio managers faded that move to lessen its impact.
Look for weaknesses in companies like these that can provide solutions to today's pressing issues.
I would not take an equity stake without messing around with net basis through the sale of what look to me to be well placed options mean to force profit taking, and/or adding at advantageous discounts.
The charts of TMO are positive.
The company needs to continue to reduce debt and strengthen its balance sheet.
Prices appear to be losing upward momentum and overbought when using the stochastic indicator, so caution is in order.
For this science and technology company, it's hard to see a pattern that justifies going long right away.
Despite getting hit with allegations last week, General Electric still has name, history and size.
And just why do we have a federal debt ceiling, anyway? An argument for doing away with it.
Here are my five rules for handling earnings season.
Those long on DHR should continue to hold, risking a close below $135 -- around $185 is a potential upside price target.
Negative political pressure is being felt in an overbearing way on the entire healthcare sector.
Monday was a demonstration of pretty much everything analysts can throw at stocks to get you out while the getting is still good.
Time could run out before Larry Culp can complete his turnaround plan at GE.
GE stock hasn't solved its free cash flow conundrum, and might not for some time, says a key analyst.